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Recently, transcranial magnetic stimulation (TMS) 
has increasingly been used to investigate the 
neurobiology of schizophrenia. In those studies, 
researchers applied TMS in combination with motor 
evoked potentials (TMS/MEPs) and high density 
electroencephalograms (TMS/hd-EEG)[1].  The 
studies revealed significant impairments in cortical 
excitability, inhibition, and oscillatory activity, which are 
more prominent in the frontal brain areas, in patients 
suffering from schizophrenia compared to healthy 
controls[1]. Future TMS studies may help explain the 
underlying neurobiology of schizophrenia, and TMS 
may help monitor and perhaps further optimize the 
effectiveness of treatment interventions in patients with 
this disease. However, despite the potential of using 
TMS in the investigation of the underlying neurobiology 
of schizophrenia, three critical notes are essential.
First, so far, TMS studies on schizophrenia have 
been neither robust, consistent, nor standardized 
enough and have had high risks of publication bias, 
as was recently concluded in a large systematic 
review of forty-one trials by Dougall and colleagues[2]. 
Studies differ in numerous variables, for example, the 
stimulation intensity or length, the areas of the brain 
that are stimulated, and the design of the same TMS 
condition. Those variables could have great impact on 
the effects of TMS in the studied population. Therefore, 
better, well-developed TMS studies that test specific 
underlying neurobiological working mechanisms in 
schizophrenia are warranted. Moreover, schizophrenia 
is not a static, but rather a dynamic, disorder; therefore, 
TMS studies should focus more on patients with different 
stages of schizophrenia, i.e. patients experiencing 
their first episode of schizophrenia versus patients with 
chronic schizophrenia.
Second, within the studies, insufficient attention has 
been paid to the safety of using TMS on patients with 
schizophrenia. This is remarkable considering that 
a vivid discussion of the risks of using TMS to treat 
psychiatric patients is ongoing[3]. From the literature, for 
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instance, human subjects, after having been treated with 
TMS, are known to suffer from minor complaints, such 
as headaches, pain due to burns caused by the scalp 
electrodes, local pain, etc.[4,5], and major complaints, 
such as mood changes, seizures, induction of hyper- 
or hypomania, etc.[4,5]. Obviously, in an extremely 
vulnerable population, such as patients suffering 
from schizophrenia, those side-effects might be more 
prominent and may lead to even more adverse events 
and difficulties in the patient’s life.
Third, as to the underlying neurobiology and possible 
treatment interventions of TMS in patients with 
schizophrenia, the clinical diagnostic issue of the 
heterogeneity of the disorder, which is a typical 
characteristic of schizophrenia, is not taken into 
account[6]. Although the symptoms may be common, 
schizophrenia may have many different causes that 
are influenced by genetic and environmental factors, 
resulting in a very heterogenic population of patients[7]. 
The answers to the questions of how informative the 
TMS findings that have been collected on schizophrenia 
so far[1] with respect to those subtypes of patient groups 
with schizophrenia are and what those findings mean at 
the individual patient level (e.g. with respect to gender 
differences, interactions with individual pharmacological 
treatments, etc.) remain unclear.
To conclude, the critical issues mentioned above 
are shown in Figure 1. If progress is to be made 
in understanding the underlying neurobiology of 
schizophrenia and in particular, if safe TMS-based 
treatments are to be developed for patients suffering 
from this disease, these issues need to be addressed 
in future, well-designed TMS studies. The results 
of such studies should more clearly expose the full 
potential of using TMS in the treatment of patients with 
schizophrenia.
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Figure 1: Summarizing the main issues regarding TMS for 
schizophrenia. TMS: transcranial magnetic stimulation
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